Old Web
English
Sign In
Acemap
>
authorDetail
>
M Batovsky
M Batovsky
Ulcerative colitis
Medicine
Mesalazine
Population
Gastroenterology
3
Papers
209
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Once-daily versus three-times-daily mesalazine granules in active ulcerative colitis: A double-blind, double-dummy, randomised non-inferiority trial
2009
Gut
Wolfgang Kruis
G Kiudelis
István Rácz
I. A. Gorelov
Juris Pokrotnieks
Marek Horynski
M Batovsky
J. Kykal
S Boehm
Roland Greinwald
Ralph Mueller
Show All
Source
Cite
Save
Citations (172)
P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study
2009
Journal of Crohns & Colitis
Wolfgang Kruis
Laimas Jonaitis
Limas Kupcinskas
Juris Pokrotnieks
G. Acute
Tatyana L. Mikhailova
Marek Horynski
M Batovsky
Y.S. Lozinskii
István Rácz
K. Kull
Aleksandar Včev
M. Faszczyk
Roland Greinwald
Ralph Mueller
Show All
Source
Cite
Save
Citations (0)
Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis
2006
Alimentary Pharmacology & Therapeutics
Peter R. Gibson
Bohumil Fixa
B. Pekárková
M Batovsky
Graham L. Radford-Smith
J Tibitanzl
Libor Gabalec
Timothy H. Florin
Roland Greinwald
Show All
Source
Cite
Save
Citations (37)
1